MRNA-002

MRNA-002 is an investigational substance being studied for primary hyperoxaluria type 1 (PH1). It is not yet an authorised medicine. The only clinical trial found for this substance is a phase 1/2 study that is currently authorised but not yet recruiting participants.^[1]

What is MRNA-002?

MRNA-002 is an investigational drug, meaning it has not been approved for use outside of clinical trials. It is being developed for the treatment of primary hyperoxaluria type 1, a rare inherited disorder. In this condition, the liver produces too much oxalate, which can lead to kidney stones and kidney damage. MRNA-002 is not the same as the mRNA vaccines used for COVID-19, such as Comirnaty or the Moderna vaccine, which are authorised for preventing infectious disease.^[2][3] The name "MRNA-002" suggests it may be an mRNA-based therapy, but the trial registry does not state its exact class or mechanism.

How does MRNA-002 work?

The trial registry does not describe the mechanism of action of MRNA-002. Messenger RNA (mRNA) therapies in general work by giving cells instructions to make a specific protein. For example, mRNA cancer therapies are being studied to help the immune system recognise and attack cancer cells.^[4] mRNA vaccines for COVID-19 instruct cells to make a viral protein so the immune system can learn to fight the virus.^[2] However, no source in this data states how MRNA-002 is intended to work in PH1.

Which conditions is MRNA-002 studied for?

• Primary hyperoxaluria type 1 (PH1) – a rare genetic condition in which the liver makes too much oxalate, leading to kidney stones and possible kidney failure.^[1]

How is MRNA-002 given?

MRNA-002 is given as a solution for intravenous infusion, meaning it is delivered directly into a vein.^[1] No other formulations or routes of administration are mentioned in the available data.

What do the clinical trials show?

There is one clinical trial of MRNA-002. It is a phase 1/2 study, which means it is an early-stage trial combining the first tests in humans with a preliminary look at effectiveness. The trial is currently authorised, meaning it has received regulatory approval to begin, but it is not yet recruiting.^[1]

What is being measured?

The main outcome is the incidence and severity of treatment-emergent adverse events, including serious adverse events. In plain words, the trial will record how often side effects occur, how severe they are, and whether any serious medical problems arise during treatment.^[1]

Who can take part?

The trial plans to enrol 23 participants with primary hyperoxaluria type 1.^[1] The registry does not list detailed eligibility criteria such as age limits or kidney function requirements.

What side effects are known?

The side effects of MRNA-002 are not yet known. The trial is designed to measure them for the first time in humans.^[1] No supplementary source in this data describes side effects specific to MRNA-002. mRNA vaccines and therapies can cause immune-related reactions, but those products are different from MRNA-002 and their side effect profiles do not apply directly.^[5]